Object's details: Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)

Provider:Akademicka Platforma Czasopism

Description

Title:
Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)
Creator:
Żelazny, Przemysław;
Filipczak, Joanna;
Sygacz, Oliwer;
Bróż, Sebastian;
Dankiewicz, Sara;
Swora, Aleksandra;
Borowik, Joanna;
Brodowski, Wojciech;
Pawłowski, Piotr;
Basta-Arciszewska, Katarzyna
Description:
Introduction: Heart failure affects an estimated 23 million people, as many as 50% of whom suffer from a heart failure with reduced ejection fraction (HFrEF), in which the left ventricle ejection fraction is <40% and is accompanied by clinical symptoms. Given the high mortality rate in this group of patients and the continuous suboptimal control of the condition, novel pharmacotherapy regimens are needed to slow the progression of the disease. Preliminary studies report a positive effect of including an angiotensin receptor antagonist and neprilysin inhibitors (ARNIs) in this group of patients. Aim of the study: The aim of the study was to summarize the benefits of ARNI in a group of patients with HFrEF. Methods and materials: This article is based on the literature found in PubMed Database with use of keywords such as “ARNI”, “neprilysin inhibition”, HFrEF”, “heart failure” Results: The benefits of ARNI therapy in patients with HFrEF originate from reversing myocardial remodeling and increasing left ventricular ejection fraction. ARNI therapy is associated with reduced number of hospitalizations and a lower need for intensive treatment. In addition, ARNI use reduces the risk of cardiovascular death and is responsible for lower overall mortality rate compared to pharmacotherapy with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs). Conclusion: ARNIs in patients with HFrEF have a positive effect on the rate of cardiovascular hospitalization, as well as reducing cardiovascular-related mortality and total mortality. Future research studies should evaluate the predictive factors of response to treatment with this group of drugs using larger groups of patients.
Object availability:
free access
Rights:
Prawa autorskie (c) 2022 Przemysław Żelazny, Joanna Filipczak, Oliwer Sygacz, Sebastian Bróż, Sara Dankiewicz, Aleksandra Swora, Joanna Borowik, Wojciech Brodowski, Piotr Pawłowski, Katarzyna Basta-Arciszewska;
http://creativecommons.org/licenses/by-nc-sa/4.0
Date:
2022.09.08
Type:
info:eu-repo/semantics/article;
info:eu-repo/semantics/publishedVersion
Language:
English
Source:
Journal of Education, Health and Sport; Vol. 12 No. 9 (2022); 583-588;
Journal of Education, Health and Sport; Tom 12 Nr 9 (2022); 583-588;
2391-8306
Format:
application/pdf
Publisher:
Nicolaus Copernicus University, Toruń, Poland
Relation: https://apcz.umk.pl/JEHS/article/view/39770/33191
Subject:
ARNI;
neprilysin inhibition;
HFrEF;
heart failure
Identifier: https://apcz.umk.pl/JEHS/article/view/39770
Data provider:
Akademicka Platforma Czasopism

Similar objects

Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)

Date:2022.09.08

Type:text

Cough as the first symptom of chronic heart failure: A case report of a 72-year-old woman

Creator:Sroczyńska, Paulina | Sroczyński, Jan | Mielczarek, Maja

Date:2025.02.16

Type:text

SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology

Date:2023.10.03

Type:text

Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review

Date:2024.07.23

Type:text

Bupropion - an antidepressant drug with broad therapeutic potential

Date:2022.09.08

Type:text

How to restore your voice? - rehabilitation methods after laryngectomy

Date:2022.09.15

Type:text

Ormond's disease - the current state of knowledge about diagnosis and treatment

Date:2022.09.08

Type:text

Diagnosis and treatment of mental disorders – a review of the scientific literature

Date:2022.09.08

Type:text

Federacja Bibliotek Cyfrowych

Object's details: Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)

Description

Similar objects